Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review)
Chronic heart failure is a global cardiac problem. The last decade can rightly be called a breakthrough in the treatment of this nosology, due to the emergence of a new group of drugs – SGLT2 inhibitors (gliflozins), which, both in patients with initial heart failure with different ejection fraction...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Siberian Branch Publishing House
2022-12-01
|
| Series: | Сибирский научный медицинский журнал |
| Subjects: | |
| Online Access: | https://sibmed.elpub.ru/jour/article/view/929 |
| _version_ | 1826575729166385152 |
|---|---|
| author | O. V. Tsygankova O. V. Timoshchenko O. V. Tuzovskaya L. D. Latyntseva K. Yu. Nikolaev |
| author_facet | O. V. Tsygankova O. V. Timoshchenko O. V. Tuzovskaya L. D. Latyntseva K. Yu. Nikolaev |
| author_sort | O. V. Tsygankova |
| collection | DOAJ |
| description | Chronic heart failure is a global cardiac problem. The last decade can rightly be called a breakthrough in the treatment of this nosology, due to the emergence of a new group of drugs – SGLT2 inhibitors (gliflozins), which, both in patients with initial heart failure with different ejection fraction, and in the presence of risk factors for its development, have a persistent positive impact on the number of hospitalizations for heart failure. A number of pleiotropic effects of SGLT2 inhibitors are also attractive to the clinician, which include moderate weight loss, a decrease in body fat in visceral fat depots, a decrease in the level of hepatic transaminases in the blood, stimulation of erythropoiesis, which organically complements the strategy of complex cardiorenometabolic protection and emphasizes the unique role of this class drugs in modern cardiology. In the near future, we will have to learn the results of the ongoing multiple studies of gliflozin, which is highly likely to open new historical horizons in the treatment of patients with cardiovascular diseases, including various categories of patients with acute and chronic heart failure. |
| first_indexed | 2024-03-08T14:33:30Z |
| format | Article |
| id | doaj.art-e124ef8e198e4b14b4fb7eda952fac90 |
| institution | Directory Open Access Journal |
| issn | 2410-2512 2410-2520 |
| language | Russian |
| last_indexed | 2025-03-14T13:19:19Z |
| publishDate | 2022-12-01 |
| publisher | Russian Academy of Sciences, Siberian Branch Publishing House |
| record_format | Article |
| series | Сибирский научный медицинский журнал |
| spelling | doaj.art-e124ef8e198e4b14b4fb7eda952fac902025-02-28T13:43:58ZrusRussian Academy of Sciences, Siberian Branch Publishing HouseСибирский научный медицинский журнал2410-25122410-25202022-12-0142641410.18699/SSMJ20220601459Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review)O. V. Tsygankova0O. V. Timoshchenko1O. V. Tuzovskaya2L. D. Latyntseva3K. Yu. Nikolaev4Research Institute of Internal and Preventive Medicine – Branch of the Federal Research Center Institute of Cytology and Genetics SB RAS; Novosibirsk State Medical University of Minzdrav of RussiaResearch Institute of Internal and Preventive Medicine – Branch of the Federal Research Center Institute of Cytology and Genetics SB RASResearch Institute of Internal and Preventive Medicine – Branch of the Federal Research Center Institute of Cytology and Genetics SB RASResearch Institute of Internal and Preventive Medicine – Branch of the Federal Research Center Institute of Cytology and Genetics SB RASResearch Institute of Internal and Preventive Medicine – Branch of the Federal Research Center Institute of Cytology and Genetics SB RASChronic heart failure is a global cardiac problem. The last decade can rightly be called a breakthrough in the treatment of this nosology, due to the emergence of a new group of drugs – SGLT2 inhibitors (gliflozins), which, both in patients with initial heart failure with different ejection fraction, and in the presence of risk factors for its development, have a persistent positive impact on the number of hospitalizations for heart failure. A number of pleiotropic effects of SGLT2 inhibitors are also attractive to the clinician, which include moderate weight loss, a decrease in body fat in visceral fat depots, a decrease in the level of hepatic transaminases in the blood, stimulation of erythropoiesis, which organically complements the strategy of complex cardiorenometabolic protection and emphasizes the unique role of this class drugs in modern cardiology. In the near future, we will have to learn the results of the ongoing multiple studies of gliflozin, which is highly likely to open new historical horizons in the treatment of patients with cardiovascular diseases, including various categories of patients with acute and chronic heart failure.https://sibmed.elpub.ru/jour/article/view/929sglt2 inhibitorsgliflozinschronic heart failuretype 2 diabetes mellitusanemianon-alcoholic fatty liver disease |
| spellingShingle | O. V. Tsygankova O. V. Timoshchenko O. V. Tuzovskaya L. D. Latyntseva K. Yu. Nikolaev Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review) Сибирский научный медицинский журнал sglt2 inhibitors gliflozins chronic heart failure type 2 diabetes mellitus anemia non-alcoholic fatty liver disease |
| title | Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review) |
| title_full | Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review) |
| title_fullStr | Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review) |
| title_full_unstemmed | Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review) |
| title_short | Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review) |
| title_sort | potential new application points of sglt2 inhibitors in patients with heart failure in combination with diabetes mellitus non alcoholic fatty liver disease and anemia literature review |
| topic | sglt2 inhibitors gliflozins chronic heart failure type 2 diabetes mellitus anemia non-alcoholic fatty liver disease |
| url | https://sibmed.elpub.ru/jour/article/view/929 |
| work_keys_str_mv | AT ovtsygankova potentialnewapplicationpointsofsglt2inhibitorsinpatientswithheartfailureincombinationwithdiabetesmellitusnonalcoholicfattyliverdiseaseandanemialiteraturereview AT ovtimoshchenko potentialnewapplicationpointsofsglt2inhibitorsinpatientswithheartfailureincombinationwithdiabetesmellitusnonalcoholicfattyliverdiseaseandanemialiteraturereview AT ovtuzovskaya potentialnewapplicationpointsofsglt2inhibitorsinpatientswithheartfailureincombinationwithdiabetesmellitusnonalcoholicfattyliverdiseaseandanemialiteraturereview AT ldlatyntseva potentialnewapplicationpointsofsglt2inhibitorsinpatientswithheartfailureincombinationwithdiabetesmellitusnonalcoholicfattyliverdiseaseandanemialiteraturereview AT kyunikolaev potentialnewapplicationpointsofsglt2inhibitorsinpatientswithheartfailureincombinationwithdiabetesmellitusnonalcoholicfattyliverdiseaseandanemialiteraturereview |